Last updated: August 27, 2026
Permax, Eli Lilly’s brand of pergolide mesylate, lost its U.S. commercial market after FDA-linked safety concerns over cardiac-valvular disease led to voluntary withdrawal in 2007. The product has no meaningful current U.S. pharmaceutical revenue base, no active U.S. Orange Book exclusivity position, and no conventional biosimilar risk because pergolide is a small-molecule drug. Commercial value shifted from human Parkinson’s disease treatment to veterinary use, primarily through pergolide products for equine pituitary pars intermedia dysfunction.
What was Permax and how was it used?
Permax was an oral dopamine agonist containing pergolide mesylate. It was approved in the United States as an adjunct to levodopa and carbidopa for the management of Parkinson’s disease. Pergolide stimulated dopamine receptors and was used when levodopa-based therapy alone did not provide adequate symptom control.
| Attribute |
Permax |
| Active ingredient |
Pergolide mesylate |
| Drug class |
Dopamine receptor agonist |
| Original sponsor |
Eli Lilly and Company |
| Primary human indication |
Adjunct treatment of Parkinson’s disease |
| Dosage form |
Oral tablets |
| U.S. regulatory status |
Withdrawn from commercial distribution in 2007 |
| Current U.S. human market |
No established Permax market |
| Current veterinary market |
Pergolide products for horses |
| Biosimilar exposure |
None; small molecule |
| Principal commercial risk |
Regulatory withdrawal and replacement by newer Parkinson’s therapies |
Pergolide competed with bromocriptine and later dopamine agonists such as pramipexole, ropinirole and rotigotine. Its clinical role narrowed as safer or more convenient alternatives gained adoption.
When did Permax lose exclusivity and when was it withdrawn?
Permax’s commercial decline resulted from both ordinary generic competition and safety-related market withdrawal. FDA stated that new data associated pergolide with valvular heart disease and that the product’s benefits no longer outweighed its risks for the approved U.S. indication.[1]
Permax U.S. regulatory timeline
| Date |
Event |
| 1988 |
FDA approved Permax for adjunctive Parkinson’s disease treatment |
| 1990s |
Pergolide competed with other dopamine agonists and generic products |
| 2002-2006 |
Studies and regulatory reviews raised concerns over cardiac-valvular effects associated with ergot-derived dopamine agonists |
| March 2007 |
FDA announced voluntary withdrawal of Permax from the U.S. market |
| 2007 |
Lilly discontinued U.S. commercial distribution |
| After 2007 |
Human use declined sharply in the United States; veterinary use continued under separate products |
The withdrawal was not a normal patent-expiration event. It was a regulatory and safety event that accelerated the collapse of branded and generic human demand.
What patents protected Permax?
Permax’s original patent estate is no longer a material U.S. exclusivity barrier. The relevant composition-of-matter and product patents, to the extent they covered pergolide or its salt forms, expired decades ago or became commercially irrelevant after generic entry and withdrawal.
U.S. patent position
The current business conclusion is straightforward:
- No active Permax patent is known to preserve U.S. human-market exclusivity.
- No current Orange Book listing gives Permax a meaningful branded barrier.
- Any historical composition, formulation or manufacturing patents would have expired before the 2007 withdrawal or would no longer block generic commercialization.
- Patent protection is not the principal reason human pergolide is absent from the U.S. market.
FDA’s Orange Book framework applies to approved drug products with listed patents and exclusivity. A withdrawn product does not provide a practical reference-product platform for a new Paragraph IV market challenge.[2]
What formulations were protected?
Permax was marketed as an oral tablet. The principal historical IP categories would have included:
- Pergolide or pergolide mesylate composition claims.
- Tablet formulations and dosage strengths.
- Manufacturing and salt-form processes.
- Parkinson’s disease methods of treatment.
Those categories do not create a current commercial moat. Generic pergolide products were available in the United States before withdrawal, and safety restrictions eliminated the commercial value of maintaining a conventional Permax franchise.
What is the Orange Book status of Permax?
Permax does not have a commercially operative Orange Book position in the United States. FDA withdrawal removed the brand from the active commercial market, while the historical product’s patent and exclusivity periods have expired.
The Orange Book does not create continuing market protection for an abandoned product. A company seeking to reintroduce pergolide would face regulatory requirements tied to the drug’s safety profile, manufacturing quality, clinical labeling and post-market risk management rather than a patent dispute with Lilly.
A future sponsor could pursue:
- A new drug application for a human indication.
- A 505(b)(2) application relying partly on published literature or historical findings.
- A veterinary pathway for an animal indication.
- A reformulated product with new dosing, delivery or risk-management features.
Each pathway would require a new commercial and regulatory thesis.
What caused the Permax market decline?
The principal market forces were safety, therapeutic substitution and generic erosion.
Cardiac-valvular toxicity
Pergolide belongs to the ergot-derived dopamine agonist class. Regulatory agencies associated pergolide exposure with fibrotic valvular heart disease and recommended echocardiographic monitoring in jurisdictions where the drug remained available.[1,3]
The safety issue affected demand in four ways:
- Physicians shifted patients to non-ergot dopamine agonists.
- Regulators restricted or removed human indications.
- Payers had little incentive to preserve access to an older generic drug.
- The product became commercially unattractive for the original sponsor.
Therapeutic substitution
Parkinson’s disease treatment moved toward pramipexole, ropinirole, rotigotine and other therapies with broader contemporary prescribing support. Levodopa remained central, while non-ergot dopamine agonists displaced pergolide in patients requiring adjunctive treatment.
Generic competition
Before withdrawal, generic pergolide reduced Permax pricing power. Generic entry typically compresses branded share and average selling price, particularly for oral tablets with no meaningful delivery-system differentiation.
Regulatory uncertainty
The withdrawal eliminated the commercial predictability needed for investment in promotion, manufacturing scale and clinical development. Even if demand had remained, the required cardiovascular monitoring and risk communication would have increased the cost of treatment.
What is the financial trajectory of Permax?
Permax revenue followed a four-stage trajectory: launch and adoption, generic erosion, safety-driven contraction, and post-withdrawal collapse.
| Stage |
Financial direction |
Main driver |
| Initial commercialization |
Growth |
Adoption as adjunct Parkinson’s therapy |
| Mature brand period |
Pressure |
Competing dopamine agonists and generic entry |
| 2002-2007 |
Sharp decline |
Valvular-heart-disease concerns and physician substitution |
| After 2007 |
Near-zero U.S. Permax revenue |
Voluntary withdrawal |
Eli Lilly did not establish a separately reported Permax revenue line in its principal public financial reporting. The company generally reported products within broader portfolio categories rather than disclosing complete product-level revenue for an older product of this scale. A reliable standalone Permax revenue series therefore does not exist in Lilly’s public annual-report disclosures.
Revenue exposure
Permax’s direct revenue exposure became immaterial after withdrawal. The more significant financial effects were indirect:
- Lost U.S. branded sales.
- Elimination of promotional and distribution activity.
- Reduced manufacturing utilization for the product.
- Potential inventory and supply-chain costs during discontinuation.
- Lower value of historical human-market regulatory assets.
Lilly’s broader financial performance was not dependent on Permax after the product had matured and competing products had expanded. The withdrawal was strategically important for the product but not a material driver of Lilly’s consolidated revenue trajectory.
Who competes with Permax?
Permax competed in the Parkinson’s disease dopamine-agonist segment rather than in a standalone pergolide market.
| Competitor |
Active ingredient |
Competitive position |
| Parlodel and generics |
Bromocriptine |
Older ergot-derived dopamine agonist |
| Mirapex and generics |
Pramipexole |
Major non-ergot substitute |
| Requip and generics |
Ropinirole |
Major non-ergot substitute |
| Neupro |
Rotigotine |
Transdermal dopamine agonist |
| Levodopa/carbidopa products |
Levodopa/carbidopa |
Core Parkinson’s treatment and adjunctive comparator |
Non-ergot dopamine agonists gained importance because they avoided the specific valvular-fibrosis concerns associated with ergot-derived agents. This shifted the market from direct price competition to safety-adjusted therapeutic substitution.
Which companies are challenging Permax today?
No meaningful current U.S. company is challenging Permax through a conventional Paragraph IV patent litigation strategy. The product has no active branded exclusivity position that would justify a standard generic challenge.
Paragraph IV exposure
Paragraph IV litigation is not a current Permax market issue because:
- Historical patents have expired.
- Permax is withdrawn from the U.S. market.
- Generic pergolide was already present before withdrawal.
- A new entrant would face regulatory and commercial barriers rather than patent barriers.
Any future sponsor seeking U.S. human commercialization would likely need to address FDA’s safety history and establish a viable benefit-risk profile. Patent litigation would be secondary.
Biosimilar risk
Permax has no biosimilar exposure. Pergolide is a chemically synthesized small molecule, not a biologic. The relevant competitive risks are:
- Generic small-molecule entry.
- Therapeutic substitution.
- Reimbursement restrictions.
- Safety-driven prescribing avoidance.
- Veterinary product competition.
What is the current veterinary market for pergolide?
Pergolide retained commercial value in veterinary medicine, especially for horses with pituitary pars intermedia dysfunction, commonly called equine Cushing’s disease.
The FDA approved Prascend, a pergolide mesylate product for horses, in 2011. Boehringer Ingelheim markets Prascend in the United States.[4] This created a separate veterinary franchise after the human Permax business had disappeared.
Human versus veterinary economics
| Factor |
Permax human market |
Pergolide veterinary market |
| Primary disease |
Parkinson’s disease |
Equine pituitary pars intermedia dysfunction |
| Regulatory status |
Withdrawn in U.S. |
Approved veterinary products available |
| Prescriber |
Neurologist or physician |
Equine veterinarian |
| Main risk |
Valvular heart disease |
Veterinary labeling and animal-safety controls |
| Competitive structure |
Highly substituted |
More specialized and indication-specific |
| Patent value |
Historical and expired |
Product, formulation and regulatory exclusivity may be more relevant |
| Revenue outlook |
No meaningful U.S. growth |
Niche, recurring veterinary demand |
Veterinary pergolide demand is supported by chronic treatment, disease prevalence in older horses and the absence of a direct replacement with equivalent clinical positioning. Its market is much smaller than the former human Parkinson’s market but can support a focused branded product.
What manufacturing and IP barriers affect pergolide?
Manufacturing barriers are moderate rather than fundamental. Pergolide is a small molecule, and the active ingredient is not inherently difficult to synthesize at commercial scale. The more important barriers are regulatory and quality-related.
A commercial manufacturer must control:
- Active pharmaceutical ingredient purity.
- Salt-form consistency.
- Tablet uniformity at low doses.
- Stability and packaging.
- Impurity profiles.
- Veterinary or human good manufacturing practice compliance.
- Product-specific safety labeling.
For a human product, cardiovascular risk management would be the principal barrier. A sponsor would also need a credible indication, a defensible dosing strategy and a market-access plan against established Parkinson’s medicines.
For veterinary products, manufacturing complexity is lower, but the sponsor still needs approved labeling, validated production and distribution through the animal-health channel.
How strong is the Permax patent estate?
The historical Permax patent estate is commercially weak. Its practical strength is low because the relevant human-market patents and exclusivity periods are expired, while the product itself was withdrawn.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Expired or commercially obsolete |
| Formulation protection |
No current known barrier to generic substitution |
| Method-of-use protection |
Expired or irrelevant to current U.S. human marketing |
| Orange Book protection |
No meaningful active position |
| Paragraph IV deterrence |
Low |
| Manufacturing protection |
Potentially relevant only to specific process claims, not market control |
| Veterinary product protection |
Product-specific rights may differ from historical Permax rights |
A new veterinary formulation may have its own regulatory exclusivity or patent protection, but that protection would not revive Permax’s historical human franchise.
What generic launch risks exist for a future pergolide product?
A future human generic launch would face limited patent risk but substantial commercial and regulatory risk.
Generic launch scenario
A manufacturer could theoretically pursue an abbreviated pathway if an approved reference product and applicable regulatory pathway were available. The business case would remain difficult because:
- Human U.S. demand is limited after the withdrawal.
- Physicians have established alternatives.
- Safety monitoring may reduce prescribing.
- Payers may not reward reentry into a mature dopamine-agonist segment.
- The sponsor could face post-market surveillance obligations.
- Product liability exposure could exceed expected revenue.
A veterinary launch is more commercially credible, but it would compete with established pergolide products and require an approved animal-health application.
What litigation and settlement agreements affect Permax?
No current major U.S. patent litigation or settlement agreement is a material driver of the Permax market. The decisive event was the voluntary withdrawal and associated regulatory action, not a patent settlement.
Historical product-liability claims may have existed around ergot-derived dopamine agonists and valvular disease, but they do not create a current exclusivity framework or define the future market structure. The relevant commercial question is whether any sponsor can justify regulatory investment after accounting for safety, litigation and limited demand.
What is the geographic coverage of the pergolide market?
Pergolide’s geographic status differs by jurisdiction. The United States withdrew human Permax in 2007. European regulators also moved against human pergolide after evaluating valvular-heart-disease risks.[3] Availability in other markets has depended on national regulatory decisions, local generic supply and veterinary demand.
The strongest continuing commercial opportunity is in animal health, where pergolide remains an established treatment for equine pituitary pars intermedia dysfunction. Geographic growth is constrained by:
- Country-specific veterinary approvals.
- Prescription controls.
- Distribution requirements.
- Competition from locally approved products.
- Differing treatment practices among equine veterinarians.
Key Takeaways
- Permax was Eli Lilly’s pergolide mesylate product for adjunctive Parkinson’s disease treatment.
- FDA-linked valvular-heart-disease concerns drove U.S. withdrawal in 2007.
- Permax has no meaningful current U.S. human revenue base.
- Historical patents and exclusivity rights no longer create a commercial barrier.
- Paragraph IV challenges and biosimilar competition are not current Permax risks.
- Pramipexole, ropinirole, rotigotine and levodopa-based therapies replaced pergolide in Parkinson’s disease.
- Pergolide retained commercial value in veterinary medicine, particularly through Prascend for horses.
- The current investment opportunity is veterinary and niche, not a revival of the former human pharmaceutical market.
- Any human-market reentry would face regulatory, safety, liability and reimbursement barriers that are more significant than patent barriers.
FAQs
Is Permax still available for Parkinson’s disease in the United States?
No. FDA announced the voluntary withdrawal of Permax from the U.S. market in 2007 after concerns about cardiac-valvular disease associated with pergolide.[1]
Is pergolide the same drug as Prascend?
Prascend contains pergolide mesylate, the same active ingredient used in Permax, but it is an FDA-approved veterinary product for horses. It is not a human Parkinson’s disease product.[4]
Can a generic company still launch pergolide in the United States?
Patent expiration does not appear to be the primary barrier. A sponsor would face the absence of a viable human reference-product market, FDA safety concerns, clinical substitution and potential liability exposure.
Did Eli Lilly lose significant corporate revenue when Permax was withdrawn?
Permax revenue declined before withdrawal and was not separately reported as a major product line in Lilly’s public financial statements. The product’s withdrawal was commercially significant at the asset level but not a major driver of Lilly’s consolidated financial trajectory.
Does Permax have a meaningful patent expiration date for investors?
No single current patent expiration date controls the Permax market. The relevant historical patents and exclusivity periods are expired, and the product’s U.S. commercial status was ended by regulatory withdrawal rather than by a pending patent cliff.
References
- U.S. Food and Drug Administration. (2007, March 29). FDA announces voluntary withdrawal of pergolide products. https://www.fda.gov/
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- European Medicines Agency. (2008). Questions and answers on the withdrawal of the marketing authorisations for pergolide-containing medicines. https://www.ema.europa.eu/
- U.S. Food and Drug Administration. (2011). FDA approves Prascend for horses with pituitary pars intermedia dysfunction. https://www.fda.gov/ ветерinarian.
